AIM
PVLA

Alambic Investment Management’s Palvella Therapeutics PVLA Stock Holding History

Alambic Investment Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-136
Closed -$23K – 47
2020
Q3 		$23K Buy
+136
New +$31K 0.25% 72
2019
Q1 		– Sell
-276
Closed -$59K – 401
2018
Q4 		$59K Buy
+276
New +$85.6K 0.02% 289
2018
Q3 		– Sell
-1,001
Closed -$406K – 376
2018
Q2 		$406K Buy
1,001
+87
+10% +$41.4K 0.11% 232
2018
Q1 		$499K Buy
+914
New +$566K 0.07% 316

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alambic Investment Management's PVLA Position: Q4 2020 in Review

Alambic Investment Management sold out of Palvella Therapeutics (PVLA) in Q4 2020, closing a stake of 136 shares — an estimated $23K sold.

Alambic Investment Management first reported a position in PVLA in Q1 2018 and held it in 4 quarters. The position peaked at $499K in Q1 2018. 82 funds tracked by Wall St. Rank hold PVLA as of Q4 2020.

  • Alambic Investment Management reported no remaining Palvella Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Alambic Investment Management sold 136 Palvella Therapeutics shares in Q4 2020, an estimated $23K.
  • Alambic Investment Management first reported a position in Palvella Therapeutics in Q1 2018 and held it in 4 quarters.
  • Alambic Investment Management's Palvella Therapeutics position peaked at $499K in Q1 2018.
  • 82 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2020.

Based on Alambic Investment Management's 13F filing for Q4 2020.